miRNA Shuttle Vectors for Reducing RNAi Off-Target Toxicity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current RNAi therapies face safety concerns due to off-target toxicity and inefficient processing of siRNA vectors, particularly in vivo, where shRNA constructs demonstrate potent gene silencing but also induce toxicity, while artificial miRNA vectors show improved processing efficiency and reduced toxicity.
Innovation Solution
Development of artificial miRNA shuttle vectors that incorporate siRNA sequences within modified microRNA 30 sequences, optimizing flanking regions and processing to enhance target gene silencing while minimizing off-target effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If shRNA constructs are used for gene silencing, then gene silencing potency is improved, but off-target toxicity increases
Solution Approach 1:
The patent uses microRNA processing machinery as an intermediary system to deliver siRNA sequences. By embedding therapeutic siRNA sequences within modified microRNA 30 sequences, the invention leverages the cell's native miRNA processing pathway (Drosha and Dicer enzymes) to process and deliver the silencing sequences, thereby reducing off-target toxicity while maintaining silencing potency
Solution Approach 2:
The patent modifies the microRNA 30 sequence parameters (flanking regions, loop structure, and seed regions) to optimize processing efficiency and reduce toxicity. Specific modifications include altering the 5' and 3' flanking sequences and adjusting the loop region to enhance Dicer processing while minimizing off-target effects
2Productivity
If artificial miRNA vectors are used, then processing efficiency is improved and toxicity is reduced, but gene silencing potency may be compromised
Solution Approach 1:
The patent systematically optimizes parameters of the artificial miRNA vectors including flanking sequence length and composition, loop region structure, and seed region matching to ensure both efficient processing by cellular machinery and potent gene silencing. The modifications to microRNA 30 flanking regions enhance processing efficiency while maintained target complementarity ensures silencing potency
Solution Approach 2:
The artificial miRNA vectors are designed to perform multiple functions: they are processed by endogenous miRNA machinery (improving efficiency), they deliver therapeutic siRNA sequences (maintaining potency), and they reduce off-target toxicity (improving safety). This multi-functionality resolves the contradiction between processing efficiency and silencing potency
3Reliability
If dsRNA 30 base pairs or longer is used in mammalian cells, then gene silencing is achieved, but sequence-nonspecific responses trigger protein synthesis shutdown
Solution Approach 1:
The patent segments long dsRNA into smaller siRNA units by embedding them within microRNA 30 sequences. The microRNA processing machinery cleaves the embedded sequences into 21-23 nucleotide siRNAs, avoiding the toxic effects of long dsRNA while maintaining gene silencing efficacy through the accumulated action of multiple processed siRNA units
Solution Approach 2:
The microRNA processing pathway (Drosha and Dicer enzymes) serves as an intermediary that converts embedded siRNA sequences into mature, functional small RNAs of appropriate length. This intermediary processing step ensures that the final active molecules are short enough to avoid toxicity while retaining silencing capability
Data Source
AI summary
The present invention is directed to RNA interference (RNAi) molecules targeted against a nucleic acid sequence, and methods of using these RNAi molecules to reduce off-target toxicity.